<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01592643</url>
  </required_header>
  <id_info>
    <org_study_id>22760</org_study_id>
    <nct_id>NCT01592643</nct_id>
  </id_info>
  <brief_title>Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain</brief_title>
  <acronym>Nexis-CS0032</acronym>
  <official_title>Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine if an investigational thin shield over the&#xD;
      cornea can safely and effectively reduce or eliminate pain following Post Photorefractive&#xD;
      Keratectomy (PRK).&#xD;
&#xD;
      The thin shield is made of silicone. The materials used to make the corneal shield all have a&#xD;
      history of use in medical devices, contact lenses, and/or corneal shields and have been used&#xD;
      safely in the eye.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See above&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of maintaining vision and mitigating pain post Photorefractive Keratectomy (PRK) using an Eye Shield</measure>
    <time_frame>1 month</time_frame>
    <description>Evidence of maintaining vision and mitigating pain post Photorefractive Keratectomy (PRK) using an Eye Shield by subjective patient questionnaires and objective imaging and slit lamp examination.</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pain</condition>
  <condition>Vision Nearsighted</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eye Shield</intervention_name>
    <description>The thin shield is made of silicone. The materials used to make the corneal shield all have a history of use in medical devices, contact lenses, and/or corneal shields and have been used safely in the eye.</description>
    <other_name>Nexis Vision corneal shield</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria.&#xD;
&#xD;
          -  Subjects age 18 and older with healthy eyes.&#xD;
&#xD;
          -  Nearsightedness between -0.50 diopters and -11.00 diopters with or without astigmatism&#xD;
             of up to 3.50 diopters.&#xD;
&#xD;
        Exclusion criteria.&#xD;
&#xD;
          -  Subjects under the age of 18.&#xD;
&#xD;
          -  Patients with excessively thin corneas.&#xD;
&#xD;
          -  Patients with topographic evidence of keratoconus.&#xD;
&#xD;
          -  Patients with ectactic eye disorders.&#xD;
&#xD;
          -  Patients with autoimmune diseases.&#xD;
&#xD;
          -  Patients who are pregnant or nursing.&#xD;
&#xD;
          -  Any other anterior segment abnormality other than that associated with PRK&#xD;
&#xD;
          -  Any abnormalities associated with the eye lids&#xD;
&#xD;
          -  Uncontrolled blepharitis or dry eye&#xD;
&#xD;
          -  Prior laser treatment of the retina&#xD;
&#xD;
          -  Any ophthalmic surgery performed within three (3) months prior to study excluding PRK&#xD;
             or LASIK&#xD;
&#xD;
          -  Diagnosis of glaucoma&#xD;
&#xD;
          -  Active diabetic retinopathy&#xD;
&#xD;
          -  Clinically significant inflammation or infection within six (6) months prior to study&#xD;
&#xD;
          -  Uncontrolled systemic disease (e.g., diabetes, hypertension, etc.) in the opinion of&#xD;
             the Investigator&#xD;
&#xD;
          -  Participation in any study involving an investigational drug within the past 30&#xD;
             calendar days, or ongoing participation in a study with an investigational material&#xD;
&#xD;
          -  Intolerance or hypersensitivity to topical anesthetics, antibiotics, steroids or any&#xD;
             other pharmaceuticals that may be used pre and post surgically Specifically known&#xD;
             intolerance or hypersensitivity to contact lenses or any component of the&#xD;
             investigative material&#xD;
&#xD;
          -  A medical condition, serious concurrent illness, or extenuating circumstance that&#xD;
             would significantly decrease study compliance, including all prescribed follow-up&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, would jeopardize the safety of&#xD;
             the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward E Manche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>May 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2012</study_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Edward E. Manche</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Corneal shield</keyword>
  <keyword>PRK</keyword>
  <keyword>Myopia</keyword>
  <keyword>Pain</keyword>
  <keyword>Vision</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

